Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment

Despite the significant outcomes attained by scientific research, breast cancer (BC) still represents the second leading cause of death in women. Estrogen receptor-positive (ER+) BC accounts for the majority of diagnosed BCs, highlighting the disruption of estrogenic signalling as target for first-line treatment. This goal is presently pursued by inhibiting aromatase (AR) enzyme or by modulating Estrogen Receptor (ER) α. An appealing strategy for fighting BC and reducing side effects and resistance issues may lie in the design of multifunctional compounds able to simultaneously target AR and ER. In this paper, previously reported flavonoid-related potent AR inhibitors were suitably modified with the aim of also targeting ERα. As a result, homoisoflavone derivatives 3b and 4a emerged as well-balanced submicromolar dual acting compounds. An extensive computational study was then performed to gain insights into the interactions the best compounds established with the two targets. This study highlighted the feasibility of switching from single-target compounds to balanced dual-acting agents, confirming that a multi-target approach may represent a valid therapeutic option to counteract ER+ BC. The homoisoflavone core emerged as a valuable natural-inspired scaffold for the design of multifunctional compounds.

[1]  A. Vinggaard,et al.  An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines , 2023, Molecules.

[2]  B. Ozpolat,et al.  Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies , 2022, Cancers.

[3]  F. Belluti,et al.  Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy. , 2022, European journal of medicinal chemistry.

[4]  O. Sahin,et al.  Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies , 2021, Journal of Molecular Medicine.

[5]  Sébastien Fiorucci,et al.  ProLIF: a library to encode molecular interactions as fingerprints , 2021, Journal of Cheminformatics.

[6]  F. Belluti,et al.  Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer. , 2021, European journal of medicinal chemistry.

[7]  A. Magistrato,et al.  Computing metal-binding proteins for therapeutic benefit. , 2021, ChemMedChem.

[8]  P. Fernandes,et al.  Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs. , 2020, Biochimie.

[9]  Aakash Saha,et al.  Frontiers of metal-coordinating drug design , 2020, Expert opinion on drug discovery.

[10]  Alessandra Magistrato,et al.  All-atom simulations to studying metallodrugs/target interactions. , 2020, Current opinion in chemical biology.

[11]  Alessandra Magistrato,et al.  Exploiting Cryo-EM Structural Information and All-Atom Simulations To Decrypt the Molecular Mechanism of Splicing Modulators , 2020, J. Chem. Inf. Model..

[12]  P. Fernandes,et al.  Estrogen receptor-positive (ER+) breast cancer treatment: are multi-target compounds the next promising approach? , 2020, Biochemical pharmacology.

[13]  A. Bisi,et al.  Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. , 2020, ACS medicinal chemistry letters.

[14]  A. Frontera,et al.  π‐Hole Interactions Involving Nitro Aromatic Ligands in Protein Structures , 2019, Chemistry.

[15]  Alessandra Magistrato,et al.  Post-Translational Regulation of CYP450s Metabolism As Revealed by All-Atoms Simulations of the Aromatase Enzyme , 2019, J. Chem. Inf. Model..

[16]  A. Magistrato,et al.  The Catalytic Mechanism of Steroidogenic Cytochromes P450 from All-Atom Simulations: Entwinement with Membrane Environment, Redox Partners, and Post-Transcriptional Regulation , 2019, Catalysts.

[17]  L. Casalino,et al.  A Dehydrogenase Dual Hydrogen Abstraction Mechanism Promotes Estrogen Biosynthesis: Can We Expand the Functional Annotation of the Aromatase Enzyme? , 2018, Chemistry.

[18]  J. Schmit,et al.  SLTCAP: A Simple Method for Calculating the Number of Ions Needed for MD Simulation. , 2018, Journal of chemical theory and computation.

[19]  A. Bisi,et al.  A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers , 2018, Scientific Reports.

[20]  E. Olson Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer , 2018, Journal of the advanced practitioner in oncology.

[21]  T. Skaar,et al.  Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. , 2016, Journal of medicinal chemistry.

[22]  Alessandra Magistrato,et al.  Role of Water in the Puzzling Mechanism of the Final Aromatization Step Promoted by the Human Aromatase Enzyme. Insights from QM/MM MD Simulations , 2015, J. Chem. Inf. Model..

[23]  F. Lumachi,et al.  Current medical treatment of estrogen receptor-positive breast cancer. , 2015, World journal of biological chemistry.

[24]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[25]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[26]  T. Skaar,et al.  Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. , 2015, Journal of medicinal chemistry.

[27]  D. Ghosh,et al.  Evidence for an Elevated Aspartate pKa in the Active Site of Human Aromatase* , 2014, The Journal of Biological Chemistry.

[28]  D. Ghosh,et al.  Mechanism of inhibition of estrogen biosynthesis by azole fungicides. , 2014, Endocrinology.

[29]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[30]  P. Perjési,et al.  Structural studies of seven homoisoflavonoids, six thiohomoisoflavonoids, and four structurally related compounds , 2012, Structural Chemistry.

[31]  Thomas E. Cheatham,et al.  Quantum mechanically derived AMBER‐compatible heme parameters for various states of the cytochrome P450 catalytic cycle , 2012, J. Comput. Chem..

[32]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[33]  A. Bisi,et al.  Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. , 2008, Journal of medicinal chemistry.

[34]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.

[35]  V. V. Zhurov,et al.  Binding of genistein to the estrogen receptor based on an experimental electron density study. , 2007, Journal of the American Chemical Society.

[36]  Joost VandeVondele,et al.  Gaussian basis sets for accurate calculations on molecular systems in gas and condensed phases. , 2007, The Journal of chemical physics.

[37]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[38]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[39]  A. Cavalli,et al.  Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. , 2006, Journal of medicinal chemistry.

[40]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[41]  Silvia Gobbi,et al.  Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. , 2005, Journal of medicinal chemistry.

[42]  B. Bonanni,et al.  SERMs in chemoprevention of breast cancer. , 2005, European journal of cancer.

[43]  A. Brodie,et al.  Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. , 2005, Cancer research.

[44]  Michele Parrinello,et al.  Quickstep: Fast and accurate density functional calculations using a mixed Gaussian and plane waves approach , 2005, Comput. Phys. Commun..

[45]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[46]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[47]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[48]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[49]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[50]  M. Dowsett Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .

[51]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[52]  X. Daura,et al.  Folding–unfolding thermodynamics of a β‐heptapeptide from equilibrium simulations , 1999, Proteins.

[53]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[54]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[55]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[56]  M. Teter,et al.  Separable dual-space Gaussian pseudopotentials. , 1995, Physical review. B, Condensed matter.

[57]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[58]  S. Nosé A unified formulation of the constant temperature molecular dynamics methods , 1984 .

[59]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[60]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[61]  Jian Yin,et al.  Lessons learned from comparing molecular dynamics engines on the SAMPL5 dataset , 2016, bioRxiv.

[62]  M. Castiglione‐Gertsch,et al.  Estrogen Receptor Modulators and Down Regulators , 2012, Drugs.

[63]  David A. Flockhart,et al.  Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer , 2011, Breast Cancer Research and Treatment.